Phase II Study of Apatinib in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer
Latest Information Update: 04 Mar 2020
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Apr 2017 New trial record